Abstract:The alternative splicing of PML precursor mRNA gives rise to various PML isoforms, yet their expression profile in breast cancer cells remains uncharted. We discovered that PML1 is the most abundant isoform in all breast cancer subtypes, and its expression is associated with unfavorable prognosis in estrogen receptor-positive (ER+) breast cancers. PML depletion reduces cell proliferation, invasion, and stemness, while heterologous PML1 expression augments these processes and fuels tumor growth and resistance to fulvestrant, an FDA-approved drug for ER+ breast cancer, in a mouse model. Moreover, PML1, rather than the well-known tumor suppressor isoform PML4, rescues the proliferation of PML knockdown cells. ChIP-seq analysis reveals significant overlap between PML-, ER-, and Myc-bound promoters, suggesting their coordinated regulation of target gene expression, including genes involved in breast cancer stem cells (BCSCs), such as JAG1 , KLF4 , YAP1 , SNAI1 , and MYC . Loss of PML reduces BCSC-related gene expression, and exogenous PML1 expression elevates their expression. Consistently, PML1 restores the association of PML with these promoters in PML -depleted cells. We identified a novel association between PML1 and WDR5, a key component of H3K4 methyltransferase (HMTs) complexes that catalyze H3K4me1 and H3K4me3. ChIP-seq analyses showed that the loss of PML1 reduces H3K4me3 in numerous loci, including BCSC-associated gene promoters. Additionally, PML1, not PML4, re-establishes the H3K4me3 mark on these promoters in PML -depleted cells. Significantly, PML1 is essential for recruiting WDR5, MLL1, and MLL2 to these gene promoters. Inactivating WDR5 by knockdown or inhibitors phenocopies the effects of PML1 loss, reducing BCSC-related gene expression and tumorsphere formation and enhancing fulvestrant's anticancer activity. Our findings challenge the conventional understanding of PML as a tumor suppressor, redefine its role as a promoter of tumor growth in breast cancer, and offer new insights into the unique roles of PML isoforms in breast cancer.

PML3 Orchestrates the Nuclear Dynamics and Function of TIP60

Stabilization of PML Nuclear Localization by Conjugation and Oligomerization of SUMO-3.

Microtubule-associated Protein 1 Light Chain 3 Interacts with and Contributes to Growth Inhibiting Effect of PML.

The Highly Conserved Region Within Exonuclease III-like in PML-I Regulates the Cytoplasmic Localization of PML-NBs

PML3 Interacts with TRF1 and is Essential for ALT-associated PML Bodies Assembly in U2OS Cells.

The Function of PML in P53-Dependent Apoptosis

B1 Oligomerization Regulates PML Nuclear Body Biogenesis and Leukemogenesis

Coiled-coil Domain of PML is Essential for the Aberrant Dynamics of PML-RARα, Resulting in Sequestration and Decreased Mobility of SMRT

PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.

C-terminal motifs in PML isoforms critically regulate PML-NB formation.

P53 and P21(waf1) Are Recruited to Distinct PML-Containing Nuclear Foci in Irradiated and Nutlin-3a-Treated U2OS Cells

Characterization of Endogenous Human Promyelocytic Leukemia Isoforms

The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer

Contribution of the C-Terminal Regions of Promyelocytic Leukemia Protein (pml) Isoforms Ii and V to Pml Nuclear Body Formation

Involvement of PML-I in Reformation of PML Nuclear Bodies in Acute Promyelocytic Leukemia Cells by Leptomycin B

PML Nuclear Bodies and Apoptosis.

Palmitoyltransferase ZDHHC3 is essential for the oncogenic activity of PML/RARα in acute promyelocytic leukemia

Phase Separation is Required for PML Nuclear Body Biogenesis and Function

AXIN is an Essential Co-Activator for the Promyelocytic Leukemia Protein in P53 Activation

Nuclear p62 condensates stabilize the promyelocytic leukemia nuclear bodies by sequestering their ubiquitin ligase RNF4

PML Nuclear bodies: the cancer connection and beyond